Tokyo Tape
Sign in
← I'rom Group

Quarterly report · Q1

2372.TEDINET S100RJUD
Period2023-04-01 → 2023-06-30
Filed2023-08-07
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 33
MetricValuePeriodScopeSource row
Revenue¥4.7bn2023-04-01 → 2023-06-30Cons.Net sales
Revenue¥18.4bn2022-04-01 → 2023-03-31Cons.Net sales (5-year summary)
Revenue¥4.8bn2022-04-01 → 2022-06-30Cons.Net sales
Operating income¥737m2023-04-01 → 2023-06-30Cons.Operating income
Operating income¥1.4bn2022-04-01 → 2022-06-30Cons.Operating income
Ordinary income¥1.1bn2023-04-01 → 2023-06-30Cons.Ordinary income
Ordinary income¥3.3bn2022-04-01 → 2023-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income¥1.4bn2022-04-01 → 2022-06-30Cons.Ordinary income
Profit before tax¥1.2bn2023-04-01 → 2023-06-30Cons.Income before income taxes
Profit before tax¥1.5bn2022-04-01 → 2022-06-30Cons.Income before income taxes
Net income (owners)¥891m2023-04-01 → 2023-06-30Cons.Profit loss attributable to owners of parent
Net income (owners)¥2.5bn2022-04-01 → 2023-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥1.1bn2022-04-01 → 2022-06-30Cons.Profit loss attributable to owners of parent
Net income¥891m2023-04-01 → 2023-06-30Cons.Profit loss
Net income¥1.1bn2022-04-01 → 2022-06-30Cons.Profit loss
Total assets¥36.1bnat 2023-06-30Cons.Assets
Total assets¥35.1bnat 2023-03-31Cons.Assets
Total assets¥28.2bnat 2022-06-30Cons.Total assets (5-year summary)
Total liabilities¥23.3bnat 2023-06-30Cons.Liabilities
Total liabilities¥23.0bnat 2023-03-31Cons.Liabilities
Net assets / equity¥12.8bnat 2023-06-30Cons.Net assets
Net assets / equity¥12.2bnat 2023-03-31Cons.Net assets
Net assets / equity¥11.0bnat 2022-06-30Cons.Net assets (5-year summary)
Cash and deposits¥8.5bnat 2023-06-30Cons.Cash and deposits
Cash and deposits¥9.4bnat 2023-03-31Cons.Cash and deposits
EPS (basic)¥73.662023-04-01 → 2023-06-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥210.222022-04-01 → 2023-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥88.372022-04-01 → 2022-06-30Cons.Basic earnings loss per share (5-year summary)
EPS (diluted)¥210.062022-04-01 → 2023-03-31Cons.Diluted earnings per share (5-year summary)
EPS (diluted)¥88.222022-04-01 → 2022-06-30Cons.Diluted earnings per share (5-year summary)
Equity ratio35.3%at 2023-06-30Cons.Equity to asset ratio (5-year summary)
Equity ratio34.6%at 2023-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio38.9%at 2022-06-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 62
SegmentItemPeriodValue
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2023-04-01 → 2023-06-30¥86m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2023-04-01 → 2023-06-30¥70m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2023-04-01 → 2023-06-30¥15m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2023-04-01 → 2023-06-30−¥212m
Reconciling Itemsreconcilingrevenue2023-04-01 → 2023-06-30−¥774m
Reconciling Itemsreconcilingrevenue intersegment2023-04-01 → 2023-06-30−¥774m
Reconciling Itemsreconcilingsegment profit2023-04-01 → 2023-06-30−¥328m
jpcrp040300-q1r_E05352-000Advanced Medicinal Treatmentreportable segmentrevenue2023-04-01 → 2023-06-30¥875m
jpcrp040300-q1r_E05352-000Advanced Medicinal Treatmentreportable segmentrevenue external2023-04-01 → 2023-06-30¥605m
jpcrp040300-q1r_E05352-000Advanced Medicinal Treatmentreportable segmentrevenue intersegment2023-04-01 → 2023-06-30¥269m
jpcrp040300-q1r_E05352-000Advanced Medicinal Treatmentreportable segmentsegment profit2023-04-01 → 2023-06-30¥190m
jpcrp040300-q1r_E05352-000CROreportable segmentrevenue2023-04-01 → 2023-06-30¥1.6bn
jpcrp040300-q1r_E05352-000CROreportable segmentrevenue external2023-04-01 → 2023-06-30¥1.4bn
jpcrp040300-q1r_E05352-000CROreportable segmentrevenue intersegment2023-04-01 → 2023-06-30¥137m
jpcrp040300-q1r_E05352-000CROreportable segmentsegment profit2023-04-01 → 2023-06-30¥36m
jpcrp040300-q1r_E05352-000Medical Supportreportable segmentrevenue2023-04-01 → 2023-06-30¥453m
jpcrp040300-q1r_E05352-000Medical Supportreportable segmentrevenue external2023-04-01 → 2023-06-30¥277m
jpcrp040300-q1r_E05352-000Medical Supportreportable segmentrevenue intersegment2023-04-01 → 2023-06-30¥176m
jpcrp040300-q1r_E05352-000Medical Supportreportable segmentsegment profit2023-04-01 → 2023-06-30−¥49m
jpcrp040300-q1r_E05352-000SMOreportable segmentrevenue2023-04-01 → 2023-06-30¥2.5bn
jpcrp040300-q1r_E05352-000SMOreportable segmentrevenue external2023-04-01 → 2023-06-30¥2.3bn
jpcrp040300-q1r_E05352-000SMOreportable segmentrevenue intersegment2023-04-01 → 2023-06-30¥174m
jpcrp040300-q1r_E05352-000SMOreportable segmentsegment profit2023-04-01 → 2023-06-30¥1.1bn
—segment totalrevenue2023-04-01 → 2023-06-30¥5.3bn
—segment totalrevenue external2023-04-01 → 2023-06-30¥4.6bn
—segment totalrevenue intersegment2023-04-01 → 2023-06-30¥758m
—segment totalsegment profit2023-04-01 → 2023-06-30¥1.3bn
Total Of Reportable Segments And Otherssegment totalrevenue2023-04-01 → 2023-06-30¥5.4bn
Total Of Reportable Segments And Otherssegment totalrevenue external2023-04-01 → 2023-06-30¥4.7bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2023-04-01 → 2023-06-30¥774m
Total Of Reportable Segments And Otherssegment totalsegment profit2023-04-01 → 2023-06-30¥1.1bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2022-04-01 → 2022-06-30¥23m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2022-04-01 → 2022-06-30¥3m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2022-04-01 → 2022-06-30¥19m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2022-04-01 → 2022-06-30−¥45m
Reconciling Itemsreconcilingrevenue2022-04-01 → 2022-06-30−¥357m
Reconciling Itemsreconcilingrevenue intersegment2022-04-01 → 2022-06-30−¥357m
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-06-30−¥364m
jpcrp040300-q1r_E05352-000Advanced Medicinal Treatmentreportable segmentrevenue2022-04-01 → 2022-06-30¥370m
jpcrp040300-q1r_E05352-000Advanced Medicinal Treatmentreportable segmentrevenue external2022-04-01 → 2022-06-30¥359m
jpcrp040300-q1r_E05352-000Advanced Medicinal Treatmentreportable segmentrevenue intersegment2022-04-01 → 2022-06-30¥10m
jpcrp040300-q1r_E05352-000Advanced Medicinal Treatmentreportable segmentsegment profit2022-04-01 → 2022-06-30¥40m
jpcrp040300-q1r_E05352-000CROreportable segmentrevenue2022-04-01 → 2022-06-30¥1.3bn
jpcrp040300-q1r_E05352-000CROreportable segmentrevenue external2022-04-01 → 2022-06-30¥1.3bn
jpcrp040300-q1r_E05352-000CROreportable segmentrevenue intersegment2022-04-01 → 2022-06-30¥75m
jpcrp040300-q1r_E05352-000CROreportable segmentsegment profit2022-04-01 → 2022-06-30¥61m
jpcrp040300-q1r_E05352-000Medical Supportreportable segmentrevenue2022-04-01 → 2022-06-30¥483m
jpcrp040300-q1r_E05352-000Medical Supportreportable segmentrevenue external2022-04-01 → 2022-06-30¥256m
jpcrp040300-q1r_E05352-000Medical Supportreportable segmentrevenue intersegment2022-04-01 → 2022-06-30¥226m
jpcrp040300-q1r_E05352-000Medical Supportreportable segmentsegment profit2022-04-01 → 2022-06-30¥38m
jpcrp040300-q1r_E05352-000SMOreportable segmentrevenue2022-04-01 → 2022-06-30¥2.9bn
jpcrp040300-q1r_E05352-000SMOreportable segmentrevenue external2022-04-01 → 2022-06-30¥2.9bn
jpcrp040300-q1r_E05352-000SMOreportable segmentrevenue intersegment2022-04-01 → 2022-06-30¥24m
jpcrp040300-q1r_E05352-000SMOreportable segmentsegment profit2022-04-01 → 2022-06-30¥1.7bn
—segment totalrevenue2022-04-01 → 2022-06-30¥5.1bn
—segment totalrevenue external2022-04-01 → 2022-06-30¥4.8bn
—segment totalrevenue intersegment2022-04-01 → 2022-06-30¥337m
—segment totalsegment profit2022-04-01 → 2022-06-30¥1.9bn
Total Of Reportable Segments And Otherssegment totalrevenue2022-04-01 → 2022-06-30¥5.1bn
Total Of Reportable Segments And Otherssegment totalrevenue external2022-04-01 → 2022-06-30¥4.8bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2022-04-01 → 2022-06-30¥357m
Total Of Reportable Segments And Otherssegment totalsegment profit2022-04-01 → 2022-06-30¥1.8bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 402
ItemContextValueUnit
Shareholders equityPrior1YearInstant12006000000JPY
Shareholders equityCurrentQuarterInstant12535000000JPY
Valuation difference on available for sale securitiesPrior1YearInstant107000000JPY
Valuation difference on available for sale securitiesCurrentQuarterInstant163000000JPY
Foreign currency translation adjustmentPrior1YearInstant33000000JPY
Foreign currency translation adjustmentCurrentQuarterInstant49000000JPY
Valuation and translation adjustmentsPrior1YearInstant141000000JPY
Valuation and translation adjustmentsCurrentQuarterInstant213000000JPY
Non controlling interestsPrior1YearInstant6000000JPY
Non controlling interestsCurrentQuarterInstant6000000JPY
Net assetsPrior1YearInstant12154000000JPY
Net assetsCurrentQuarterInstant12755000000JPY
Liabilities and net assetsPrior1YearInstant35129000000JPY
Liabilities and net assetsCurrentQuarterInstant36075000000JPY
Net salesPrior1YTDDuration4792000000JPY
Net salesCurrentYTDDuration4659000000JPY
Cost of salesPrior1YTDDuration2129000000JPY
Cost of salesCurrentYTDDuration2420000000JPY
Gross profitPrior1YTDDuration2662000000JPY
Gross profitCurrentYTDDuration2238000000JPY
Directors compensations sgaPrior1YTDDuration117000000JPY
Directors compensations sgaCurrentYTDDuration123000000JPY
Salaries allowances and bonuses sgaPrior1YTDDuration507000000JPY
Salaries allowances and bonuses sgaCurrentYTDDuration593000000JPY
Commission fee sgaPrior1YTDDuration48000000JPY
Commission fee sgaCurrentYTDDuration56000000JPY
Rent expenses sgaPrior1YTDDuration101000000JPY
Rent expenses sgaCurrentYTDDuration117000000JPY
Research and development expenses sgaPrior1YTDDuration100000000JPY
Research and development expenses sgaCurrentYTDDuration181000000JPY
Other sgaPrior1YTDDuration338000000JPY
Other sgaCurrentYTDDuration428000000JPY
Selling general and administrative expensesPrior1YTDDuration1213000000JPY
Selling general and administrative expensesCurrentYTDDuration1501000000JPY
Operating incomePrior1YTDDuration1449000000JPY
Operating incomeCurrentYTDDuration737000000JPY
Interest income noiPrior1YTDDuration1000000JPY
Interest income noiCurrentYTDDuration5000000JPY
Dividends income noiPrior1YTDDuration0JPY
Dividends income noiCurrentYTDDuration0JPY
Foreign exchange gains noiPrior1YTDDuration204000000JPY
Foreign exchange gains noiCurrentYTDDuration368000000JPY
Land and house rent received noiPrior1YTDDuration1000000JPY
Land and house rent received noiCurrentYTDDuration66000000JPY
Other noiPrior1YTDDuration13000000JPY
Other noiCurrentYTDDuration48000000JPY
Non operating incomePrior1YTDDuration220000000JPY
Non operating incomeCurrentYTDDuration489000000JPY
Interest expenses noePrior1YTDDuration31000000JPY
Interest expenses noeCurrentYTDDuration43000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identityconsolidated 2023-03-31pass rounding
balance sheet identityconsolidated 2023-06-30pass rounding
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2023-03-31pass
statement vs summary · net assetsconsolidated 2023-06-30pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-06-30pass
statement vs summary · net income attributable to parentconsolidated 2023-04-01/2023-06-30pass
statement vs summary · revenueconsolidated 2022-04-01/2022-06-30pass
statement vs summary · revenueconsolidated 2023-04-01/2023-06-30pass
statement vs summary · total assetsconsolidated 2023-03-31pass
statement vs summary · total assetsconsolidated 2023-06-30pass